181 related articles for article (PubMed ID: 34615721)
41. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.
Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST)
J Clin Oncol; 2010 Mar; 28(7):1247-53. PubMed ID: 20124181
[TBL] [Abstract][Full Text] [Related]
42. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor.
Li J; Gong JF; Wu AW; Shen L
Eur J Surg Oncol; 2011 Apr; 37(4):319-24. PubMed ID: 21277730
[TBL] [Abstract][Full Text] [Related]
43. Comparison of outcomes between neoadjuvant imatinib and upfront surgery in patients with localized rectal GIST: An inverse probability of treatment weighting analysis.
Ling JY; Ding MM; Yang ZF; Zhao YD; Xie XY; Shi LS; Wang HM; Cao WT; Zhang JW; Hu HB; Cai Y; Wang H; Deng YH
J Surg Oncol; 2021 Dec; 124(8):1442-1450. PubMed ID: 34494280
[TBL] [Abstract][Full Text] [Related]
44. Risk stratification models and mutational analysis: keys to optimising adjuvant therapy in patients with gastrointestinal stromal tumour.
Gronchi A
Eur J Cancer; 2013 Mar; 49(4):884-92. PubMed ID: 23206668
[TBL] [Abstract][Full Text] [Related]
45. Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib.
Joensuu H; Eriksson M; Hall KS; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Ballman KV; Leinonen M; DeMatteo RP; Reichardt P
Cancer; 2014 Aug; 120(15):2325-33. PubMed ID: 24737415
[TBL] [Abstract][Full Text] [Related]
46. Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome.
Søreide K; Sandvik OM; Søreide JA; Gudlaugsson E; Mangseth K; Haugland HK
Clin Transl Oncol; 2012 Aug; 14(8):619-29. PubMed ID: 22855146
[TBL] [Abstract][Full Text] [Related]
47. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
Heinrich MC; Maki RG; Corless CL; Antonescu CR; Harlow A; Griffith D; Town A; McKinley A; Ou WB; Fletcher JA; Fletcher CD; Huang X; Cohen DP; Baum CM; Demetri GD
J Clin Oncol; 2008 Nov; 26(33):5352-9. PubMed ID: 18955458
[TBL] [Abstract][Full Text] [Related]
48. Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors.
Gao J; Tian Y; Li J; Sun N; Yuan J; Shen L
Med Oncol; 2013 Jun; 30(2):522. PubMed ID: 23456621
[TBL] [Abstract][Full Text] [Related]
49. Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a european multicenter analysis based on ConticaGIST.
Wozniak A; Rutkowski P; Schöffski P; Ray-Coquard I; Hostein I; Schildhaus HU; Le Cesne A; Bylina E; Limon J; Blay JY; Siedlecki JA; Wardelmann E; Sciot R; Coindre JM; Debiec-Rychter M
Clin Cancer Res; 2014 Dec; 20(23):6105-16. PubMed ID: 25294914
[TBL] [Abstract][Full Text] [Related]
50. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS).
Martín J; Poveda A; Llombart-Bosch A; Ramos R; López-Guerrero JA; García del Muro J; Maurel J; Calabuig S; Gutierrez A; González de Sande JL; Martínez J; De Juan A; Laínez N; Losa F; Alija V; Escudero P; Casado A; García P; Blanco R; Buesa JM;
J Clin Oncol; 2005 Sep; 23(25):6190-8. PubMed ID: 16135486
[TBL] [Abstract][Full Text] [Related]
51. Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: implications of imatinib mesylate.
Yeh CN; Chen TW; Wu TJ; Hsueh S; Jan YY
World J Gastroenterol; 2006 Jun; 12(23):3760-5. PubMed ID: 16773696
[TBL] [Abstract][Full Text] [Related]
52. [Changes of diagnosis and treatment for gastrointestinal stromal tumors during a 18-year period in four medical centers of China].
Qiu H; Zhang P; Feng X; Chen T; Sun X; Yu J; Chen Z; Li Y; Tao K; Li G; Zhou Z
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1265-1270. PubMed ID: 27928797
[TBL] [Abstract][Full Text] [Related]
53. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
Blanke CD; Demetri GD; von Mehren M; Heinrich MC; Eisenberg B; Fletcher JA; Corless CL; Fletcher CD; Roberts PJ; Heinz D; Wehre E; Nikolova Z; Joensuu H
J Clin Oncol; 2008 Feb; 26(4):620-5. PubMed ID: 18235121
[TBL] [Abstract][Full Text] [Related]
54. Outcome of 1000 Patients With Gastrointestinal Stromal Tumor (GIST) Treated by Surgery in the Pre- and Post-imatinib Eras.
Cavnar MJ; Seier K; Curtin C; Balachandran VP; Coit DG; Yoon SS; Crago AM; Strong VE; Tap WD; Gönen M; Antonescu CR; Brennan MF; Singer S; DeMatteo RP
Ann Surg; 2021 Jan; 273(1):128-138. PubMed ID: 30946076
[TBL] [Abstract][Full Text] [Related]
55. [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].
Hong JL; Li J; Li J; Shen L
Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):386-90. PubMed ID: 22932406
[TBL] [Abstract][Full Text] [Related]
56. KIT Exon 9-Mutated Gastrointestinal Stromal Tumours: Biology and Treatment.
Napolitano A; Thway K; Smith MJ; Huang PH; Jones RL
Chemotherapy; 2022; 67(2):81-90. PubMed ID: 34983047
[TBL] [Abstract][Full Text] [Related]
57. Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes.
Burger H; den Bakker MA; Kros JM; van Tol H; de Bruin AM; Oosterhuis W; van den Ingh HF; van der Harst E; de Schipper HP; Wiemer EA; Nooter K
Cancer Biol Ther; 2005 Nov; 4(11):1270-4. PubMed ID: 16294026
[TBL] [Abstract][Full Text] [Related]
58. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
Yeh CN; Chen MH; Chen YY; Yang CY; Yen CC; Tzen CY; Chen LT; Chen JS
Oncotarget; 2017 Jul; 8(27):44121-44130. PubMed ID: 28487491
[TBL] [Abstract][Full Text] [Related]
59. Genomic Subtypes of GISTs for Stratifying Patient Response to Sunitinib following Imatinib Resistance: A Pooled Analysis and Systematic Review.
Tan S; Chen P; Ji J; Guo S; Yu D; Asakawa T; Zhou Y; Abe M; Zong L
Dis Markers; 2018; 2018():1368617. PubMed ID: 30224936
[TBL] [Abstract][Full Text] [Related]
60. Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor.
Fu Y; Hao H; Guo L; Yang G; Zhang X
Oncotarget; 2017 Feb; 8(6):10136-10144. PubMed ID: 28052037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]